RAAPID, Inc. Secures Series A Funding to Enhance AI Risk Adjustment Platform
RAAPID, Inc., based in Louisville, Kentucky, has announced the close of its Series A funding round, securing an undisclosed amount. The round was led by UPMC Enterprises, with participation from M12, Microsoft's venture fund. RAAPID specializes in a neuro-symbolic AI risk adjustment platform that offers high accuracy and return on investment (ROI) for health plans and providers.
Company Overview
Founded by Chetan Parikh, who serves as CEO, and Vatsal Ghiya, the Co-Founder and CMO, RAAPID focuses on applying advanced AI to improve medical coding and risk adjustment. The platform is designed to deliver 98% accuracy and provides audit-ready Hierarchical Condition Category (HCC) coding, which is crucial for Medicare Advantage plans and accountable care organizations.
Strategic Investment
The Series A funding led by UPMC Enterprises aims to accelerate the expansion of RAAPID’s AI platform. The investment will support the development of clinical AI applications that enhance healthcare compliance and risk adjustment workflows. The partnership with UPMC Enterprises is expected to unlock new co-development opportunities, broadening the platform's reach and capabilities.
Use of Funds
The newly secured funds will be directed towards scaling RAAPID’s platform, which is focused on enhancing accuracy and compliance in medical coding. The company plans to expand its deployment on Microsoft Azure, allowing customers to maintain data sovereignty while aligning with existing Azure commitments. Furthermore, RAAPID’s emphasis on security and regulatory standards is reinforced by its HITRUST certification and SOC 2 compliance.
Industry Context
RAAPID's platform comes at a critical time as regulatory scrutiny around risk adjustment intensifies. Increased enforcement actions and RADV audits have made compliance-first solutions a priority for healthcare organizations. RAAPID’s technology aims to provide a transparent, clinician-grounded evidence trail for diagnoses, which is vital under current audit conditions.
Looking Ahead
RAAPID aims to position its platform as a comprehensive solution to replace fragmented legacy systems. By focusing on retrospective, prospective, and audit-focused use cases, the company seeks to meet evolving regulatory expectations for transparency and explainability. CEO Chetan Parikh commented: “Neuro-Symbolic AI gives coders and compliance teams something legacy platforms do not: a transparent, clinician-grounded evidence trail behind every diagnosis.”
This Series A funding round marks a significant step for RAAPID as it continues to innovate in the healthcare IT sector, enhancing its capabilities to meet the demands of a rapidly evolving regulatory landscape.